Abstract: The present invention provides a coating composition for polyolefin resins, comprising a resin obtained by graft-copolymerizing at least one member selected from the group consisting of an ?,?-unsaturated carboxylic acid and an acid anhydride thereof with at least one member selected from the group consisting of polypropylene and a propylene-?-olefin copolymer, chlorinating the graft copolymer to give an acid-modified chlorinated polyolefin, linking a (meth)acrylic ester having one hydroxyl group to the polyolefin via an ester linkage, and then graft-copolymerizing (meth)acrylic acid monomers with the polyolefin; and a process for producing the composition.

Abstract: The present invention provides a coating composition for polyolefin resins, comprising a resin obtained by graft-copolymerizing at least one member selected from the group consisting of an &agr;,&bgr;-unsaturated carboxylic acid and an acid anhydride thereof with at least one member selected from the group consisting of polypropylene and a propylene-&agr;-olefin copolymer, chlorinating the graft copolymer to give an acid-modified chlorinated polyolefin, linking a (meth)acrylic ester having one hydroxyl group to the polyolefin via an ester linkage, and then graft-copolymerizing (meth)acrylic acid monomers with the polyolefin; and a process for producing the composition.

Abstract: An angiogenesis inhibitor and drug inhibiting the tumor metastasis exasperated by TP which comprises, as an effective component, at least one kind of compound selected from the group consisting of 2-deoxy-L-ribose, 2-deoxy-L-ribose derivatives whose hydroxyl group is methylated and/or acylated and 2-deoxy-D-ribose derivatives whose hydroxyl group is methylated and/or acylated.

Abstract: An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: ##STR1## or a pharmaceutically acceptable salt of the compound.

Abstract: Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect of antitumor drugs.

Abstract: Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is a 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is either a CO.sub.2 R.sup.8 group or a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect or antitumor drugs.